Drugs / ARC-521
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02797522 | Jun → Nov 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-04-20 | Arrowhead Pharmaceuticals | Results Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™ arrowheadpharma.com ↗
In addition, early data from the ARC-521 study indicate that RNAi therapeutics can be active against HBV gene products derived from both cccDNA and integrated HBV DNA. |
| 2016-04-28 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-04-20 | Arrowhead Pharmaceuticals | Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™ arrowheadpharma.com ↗ |
| 2016-09-07 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521 arrowheadpharma.com ↗ |
| 2016-06-09 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521 arrowheadpharma.com ↗ |
| 2016-04-28 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 arrowheadpharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARC-521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02797522 ↗ |